Literature DB >> 2564629

Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium.

M R Bristow1, R E Hershberger, J D Port, W Minobe, R Rasmussen.   

Abstract

Prenalterol (beta 1-agonist), denopamine (beta 1-agonist), and zinterol (beta 2-agonist) were partial agonists of adenylate cyclase (AC) stimulation in human ventricular myocardium obtained from nonfailing chambers whose beta 1/beta 2 receptor subtype ratio was approximately 80/20. At a concentration less than its low affinity (beta 2) Kl, betaxolol, a highly selective beta 1-antagonist, inhibited isoproterenol (non-selective agonist), denopamine, and prenalterol stimulation of AC, indicating that isoproterenol, denopamine, and prenalterol are all capable of stimulating AC through beta 1-receptor activation. At a concentration less than its low affinity (beta 1) Kl, ICI 118,551, a highly selective beta 2-agonist, inhibited both isoproterenol and zinterol stimulation of AC, indicating that isoproterenol and zinterol stimulate AC through beta 2-receptors. Zinterol stimulation of AC was mediated entirely by beta 2-receptors, inasmuch as 10(-7) M betaxolol had no effect on the zinterol dose-response curve and ICI 118,551 produced a degree of blockade (KB = 5.2 +/- 1.6 X 10(-9) M), consistent with the beta 2-receptor Kl of the latter (2.0 +/- .4 X 10(-9) M, p, not significant). In nonfailing myocardium, analysis of beta 1 versus beta 2 stimulation by the nonselective agonist isoproterenol revealed that the numerically small (19% of the total) beta 2 fraction accounted for the majority of the total adenylate cyclase stimulation. In failing ventricular chambers with a beta 1/beta 2 receptor subtype ratio reduced from 82/19 (nonfailing) to 64/36 (p less than 0.001) and a beta 1-receptor density reduced by 61% (p less than 0.001), maximal denopamine stimulation was reduced by 49% (p less than 0.001). Moreover, in preparations from failing heart, the component of denopamine stimulation that was inhibited by 10(-7) M betaxolol (beta 1 component) was reduced by 77% (p less than 0.05). Finally, in preparations derived from failing ventricular myocardium, beta 2-receptor density was not significantly decreased, but zinterol stimulation of AC was reduced by 32% (p less than 0.05). We conclude that heart failure results in subsensitivity to both selective beta 1 and beta 2 stimulation of adenylate cyclase, with beta 1 subsensitivity due to selective beta 1 receptor down-regulation and beta 2 subsensitivity due to partial uncoupling of beta 2 receptors from subsequent events in the beta 2-adrenergic pathway.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2564629

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  76 in total

Review 1.  Transcriptional regulation by cAMP in the heart.

Authors:  F U Müller; J Neumann; W Schmitz
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

Review 2.  β-Adrenergic receptor subtype signaling in heart: from bench to bedside.

Authors:  Anthony Yiu Ho Woo; Rui-ping Xiao
Journal:  Acta Pharmacol Sin       Date:  2012-01-30       Impact factor: 6.150

3.  Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effects.

Authors:  D K Rohrer; K H Desai; J R Jasper; M E Stevens; D P Regula; G S Barsh; D Bernstein; B K Kobilka
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

Review 4.  Alterations in adrenergic receptor signaling in heart failure.

Authors:  S Lamba; W T Abraham
Journal:  Heart Fail Rev       Date:  2000-03       Impact factor: 4.214

Review 5.  Therapy of idiopathic dilated cardiomyopathy with chronic beta-adrenergic blockade.

Authors:  E M Gilbert; J B O'Connell; M R Bristow
Journal:  Heart Vessels Suppl       Date:  1991

6.  Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts.

Authors:  M A Movsesian; C J Smith; J Krall; M R Bristow; V C Manganiello
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

7.  Myocardial beta-adrenoceptor density and the distribution of beta 1- and beta 2-adrenoceptor subpopulations in children with congenital heart disease.

Authors:  R Kozlik; H H Kramer; H Wicht; A Krian; J Ostermeyer; D Reinhardt
Journal:  Eur J Pediatr       Date:  1991-04       Impact factor: 3.183

8.  The Arg16Gly polymorphism of the beta2-adrenergic receptor and the natriuretic response to rapid saline infusion in humans.

Authors:  Eric M Snyder; Stephen T Turner; Michael J Joyner; John H Eisenach; Bruce D Johnson
Journal:  J Physiol       Date:  2006-05-25       Impact factor: 5.182

9.  Carvedilol tratment of chronic heart failure: a new era.

Authors:  M Bristow
Journal:  Heart       Date:  1998-06       Impact factor: 5.994

10.  Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice.

Authors:  J Turki; J N Lorenz; S A Green; E T Donnelly; M Jacinto; S B Liggett
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.